Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Vaccines

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 175 articles:
HTML format
Text format



Single Articles


    February 2018
  1. LIU R, Moss B
    Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state.
    J Virol. 2018 Feb 14. pii: JVI.00053-18. doi: 10.1128/JVI.00053.
    PubMed     Text format     Abstract available


  2. JEGASKANDA S, Mason RD, Andrews SF, Wheatley AK, et al
    Intranasal live influenza vaccine priming elicits localized B cell responses in mediastinal lymph nodes.
    J Virol. 2018 Feb 14. pii: JVI.01970-17. doi: 10.1128/JVI.01970.
    PubMed     Text format     Abstract available


  3. LOPES PP, Todorov G, Pham TT, Nesburn AB, et al
    Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8(+) TEM and TRM Cell Responses Against Herpes Infection and Disease(double dagger).
    J Virol. 2018 Feb 7. pii: JVI.02156-17. doi: 10.1128/JVI.02156.
    PubMed     Text format     Abstract available


  4. SAUNDERS KO, Santra S, Parks R, Yates NL, et al
    Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates.
    J Virol. 2018 Feb 7. pii: JVI.02035-17. doi: 10.1128/JVI.02035.
    PubMed     Text format     Abstract available


  5. WIJESUNDARA DK, Gummow J, Li Y, Yu W, et al
    Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice.
    J Virol. 2018 Feb 7. pii: JVI.02133-17. doi: 10.1128/JVI.02133.
    PubMed     Text format     Abstract available


    January 2018
  6. JANKOVICH JK, Chapman D, Hansen DT, Robida MD, et al
    Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins.
    J Virol. 2018 Jan 31. pii: JVI.02219-17. doi: 10.1128/JVI.02219.
    PubMed     Text format     Abstract available


  7. YATES NL, deCamp AC, Korber BT, Liao HX, et al
    HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
    J Virol. 2018 Jan 31. pii: JVI.01843-17. doi: 10.1128/JVI.01843.
    PubMed     Text format     Abstract available


  8. PERMAR SR, Schleiss MR, Plotkin SA
    Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.
    J Virol. 2018 Jan 17. pii: JVI.00030-18. doi: 10.1128/JVI.00030.
    PubMed     Text format     Abstract available


  9. WILLS S, Hwang KK, Liu P, Dennison SM, et al
    HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis.
    J Virol. 2018 Jan 10. pii: JVI.01552-17. doi: 10.1128/JVI.01552.
    PubMed     Text format     Abstract available


  10. ABBINK P, Kirilova M, Boyd M, Mercado N, et al
    Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.
    J Virol. 2018 Jan 3. pii: JVI.01924-17. doi: 10.1128/JVI.01924.
    PubMed     Text format     Abstract available


  11. XU K, Song Y, Dai L, Zhang Y, et al
    Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.
    J Virol. 2018 Jan 3. pii: JVI.01722-17. doi: 10.1128/JVI.01722.
    PubMed     Text format     Abstract available


    December 2017
  12. ROSTAD CA, Stobart CC, Todd SO, Molina SA, et al
    ENHANCING THE THERMOSTABILITY AND IMMUNOGENICITY OF AN RSV LIVE-ATTENUATED VACCINE BY INCORPORATING UNIQUE RSV LINE19F PROTEIN RESIDUES.
    J Virol. 2017 Dec 20. pii: JVI.01568-17. doi: 10.1128/JVI.01568.
    PubMed     Text format     Abstract available


  13. LI C, Zhou H, Zhang H, Wang S, et al
    Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.
    J Virol. 2017;91.
    PubMed     Text format    


  14. KASANI SK, Cheng HY, Yeh KE, Chang SJ, et al
    Reply to "Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein".
    J Virol. 2017;91.
    PubMed     Text format    


  15. REIS AL, Goatley LC, Jabbar T, Sanchez-Cordon PJ, et al
    Deletion of the African Swine Fever Virus Gene DP148R Does Not Reduce Virus Replication in Culture but Reduces Virus Virulence in Pigs and Induces High Levels of Protection against Challenge.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  16. ROYER DJ, Carr DJJ
    Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"
    J Virol. 2017;91.
    PubMed     Text format    


  17. GHIASI H
    Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    J Virol. 2017;91.
    PubMed     Text format    


    November 2017
  18. ERASMUS JH, Seymour RL, Kaelber JT, Kim DY, et al
    Novel insect-specific Eilat virus-based chimeric vaccine candidates provide durable, mono- and multi-valent, single dose protection against lethal alphavirus challenge.
    J Virol. 2017 Nov 29. pii: JVI.01274-17. doi: 10.1128/JVI.01274.
    PubMed     Text format     Abstract available


  19. MATASSOV D, Mire CE, Latham T, Geisbert JB, et al
    Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190.
    PubMed     Text format     Abstract available


  20. JERE KC, Chaguza C, Bar-Zeev N, Lowe J, et al
    Emergence of double- and triple-gene reassortant G1P[8] rotaviruses possessing a DS-1-like backbone post rotavirus vaccine introduction in Malawi.
    J Virol. 2017 Nov 15. pii: JVI.01246-17. doi: 10.1128/JVI.01246.
    PubMed     Text format     Abstract available


  21. MALHERBE DC, Mendy J, Vang L, Barnette PT, et al
    Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C SHIV Mucosal Challenge.
    J Virol. 2017 Nov 1. pii: JVI.01092-17. doi: 10.1128/JVI.01092.
    PubMed     Text format     Abstract available


  22. GRESETH MD, Czarnecki MW, Bluma MS, Traktman P, et al
    Isolation and Characterization of vDeltaI3 Confirms that the Vaccinia Virus SSB Plays an Essential Role in Viral Replication.
    J Virol. 2017 Nov 1. pii: JVI.01719-17. doi: 10.1128/JVI.01719.
    PubMed     Text format     Abstract available


  23. VAN ERP EA, van Kasteren PB, Guichelaar T, Ahout IML, et al
    In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  24. MONTEAGUDO PL, Lacasta A, Lopez E, Bosch L, et al
    BA71DeltaCD2: a New Recombinant Live Attenuated African Swine Fever Virus with Cross-Protective Capabilities.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    October 2017
  25. WANG X, Ku Z, Zhang X, Ye X, et al
    Structure, Immunogenicity and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
    J Virol. 2017 Oct 25. pii: JVI.01330-17. doi: 10.1128/JVI.01330.
    PubMed     Text format     Abstract available


  26. BOGDANOFF WA, Perez EI, Lopez T, Arias CF, et al
    Structural basis for the escape of human astrovirus from antibody neutralization: broad implications for rational vaccine design.
    J Virol. 2017 Oct 25. pii: JVI.01546-17. doi: 10.1128/JVI.01546.
    PubMed     Text format     Abstract available


  27. YORK J, Nunberg JH
    Epistastic interactions within the Junin virus envelope glycoprotein complex provide an evolutionary barrier to reversion in the live-attenuated Candid#1 vaccine.
    J Virol. 2017 Oct 25. pii: JVI.01682-17. doi: 10.1128/JVI.01682.
    PubMed     Text format     Abstract available


  28. SCHONE D, Hrycak CP, Windmann S, Lapuente D, et al
    Immunodominance of Adenovirus-Derived CD8+ T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  29. MURA M, Combredet C, Najburg V, Sanchez David RY, et al
    Nonencapsidated 5' Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and LGP2 but Not MDA5.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  30. MCGUIRE EP, Fong Y, Toote C, Cunningham CK, et al
    HIV exposed infants vaccinated with a MF59/rgp120 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01070-17. doi: 10.1128/JVI.01070.
    PubMed     Text format     Abstract available


  31. SHEN X, Basu R, Sawant S, Beaumont D, et al
    HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01077-17. doi: 10.1128/JVI.01077.
    PubMed     Text format     Abstract available


  32. WONG TM, Allen JD, Bebin-Blackwell AG, Carter DM, et al
    COBRA HA elicits hemagglutination-inhibition antibodies against a panel of H3N2 influenza virus co-circulating variants.
    J Virol. 2017 Oct 4. pii: JVI.01581-17. doi: 10.1128/JVI.01581.
    PubMed     Text format     Abstract available


  33. CARTER DM, Darby CA, Johnson SK, Carlock MA, et al
    Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets pre-immune to historical H1N1 influenza viruses.
    J Virol. 2017 Oct 4. pii: JVI.01283-17. doi: 10.1128/JVI.01283.
    PubMed     Text format     Abstract available


  34. GOFF PH, Hayashi T, He W, Yao S, et al
    Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    September 2017
  35. URAKAMI A, Ngwe Tun MM, Moi ML, Sakurai A, et al
    Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design.
    J Virol. 2017 Sep 27. pii: JVI.01181-17. doi: 10.1128/JVI.01181.
    PubMed     Text format     Abstract available


  36. BAGRI P, Anipindi VC, Nguyen PV, Vitali D, et al
    A novel role for IL-17 in enhancing type 1 helper T cell immunity in the female genital tract following mucosal HSV-2 vaccination.
    J Virol. 2017 Sep 27. pii: JVI.01234-17. doi: 10.1128/JVI.01234.
    PubMed     Text format     Abstract available


  37. MOONEY AJ, Gabbard JD, Li Z, Dlugolenski DA, et al
    Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    J Virol. 2017 Sep 20. pii: JVI.01579-17. doi: 10.1128/JVI.01579.
    PubMed     Text format     Abstract available


  38. ANDERSEN TK, Zhou F, Cox R, Bogen B, et al
    A DNA vaccine that targets hemagglutinin to antigen presenting cells protects mice against H7 influenza.
    J Virol. 2017 Sep 20. pii: JVI.01340-17. doi: 10.1128/JVI.01340.
    PubMed     Text format     Abstract available


  39. RYERSON MR, Richards MM, Kvansakul M, Hawkins CJ, et al
    Vaccinia virus encodes a novel inhibitor of apoptosis that associates with the apoptosome.
    J Virol. 2017 Sep 13. pii: JVI.01385-17. doi: 10.1128/JVI.01385.
    PubMed     Text format     Abstract available


  40. SAUERMANN U, Radaelli A, Stolte-Leeb N, Raue K, et al
    Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses.
    J Virol. 2017 Sep 13. pii: JVI.01120-17. doi: 10.1128/JVI.01120.
    PubMed     Text format     Abstract available


  41. PUCKETTE M, Clark BA, Smith JD, Turecek T, et al
    Foot-and-mouth disease virus 3C protease mutant L127P: Implications for FMD vaccine development.
    J Virol. 2017 Sep 6. pii: JVI.00924-17. doi: 10.1128/JVI.00924.
    PubMed     Text format     Abstract available


  42. MAGNANI DM, Silveira CGT, Ricciardi MJ, Gonzalez-Nieto L, et al
    Potent Plasmablast-Derived Antibodies Elicited by the NIH Dengue Vaccine.
    J Virol. 2017 Sep 6. pii: JVI.00867-17. doi: 10.1128/JVI.00867.
    PubMed     Text format     Abstract available


  43. SULLIVAN JT, Sulli C, Nilo A, Yasmeen A, et al
    High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers.
    J Virol. 2017 Sep 6. pii: JVI.00862-17. doi: 10.1128/JVI.00862.
    PubMed     Text format     Abstract available


  44. VERMA S, Weiskopf D, Gupta A, McDonald B, et al
    Erratum for Verma et al., "Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection".
    J Virol. 2017;91.
    PubMed     Text format    


    August 2017
  45. BROOKE CB
    Population diversity and collective interactions during influenza virus replication and evolution.
    J Virol. 2017 Aug 30. pii: JVI.01164-17. doi: 10.1128/JVI.01164.
    PubMed     Text format     Abstract available


  46. LIU X, Liang B, Ngwuta J, Liu X, et al
    Attenuated human parainfluenza virus type 1 (HPIV1) expressing the respiratory syncytial virus (RSV) fusion F glycoprotein from an added gene: effects of pre-fusion stabilization and packaging of RSV F.
    J Virol. 2017 Aug 23. pii: JVI.01101-17. doi: 10.1128/JVI.01101.
    PubMed     Text format     Abstract available


  47. HAN Q, Williams WB, Saunders KO, Seaton KE, et al
    HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces Gp41 Antibody Immunodominance in Rhesus Macaques.
    J Virol. 2017 Aug 9. pii: JVI.00923-17. doi: 10.1128/JVI.00923.
    PubMed     Text format     Abstract available


  48. PIERCE BG, Boucher EN, Piepenbrink KH, Ejemel M, et al
    Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.
    J Virol. 2017 Aug 9. pii: JVI.01032-17. doi: 10.1128/JVI.01032.
    PubMed     Text format     Abstract available


  49. GARG H, Sedano M, Plata G, Punke EB, et al
    Development of Virus like Particle Vaccine and Reporter Assay for Zika Virus.
    J Virol. 2017 Aug 9. pii: JVI.00834-17. doi: 10.1128/JVI.00834.
    PubMed     Text format     Abstract available


  50. WANG Q, Yan J, Gao GF
    Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design.
    J Virol. 2017 Aug 2. pii: JVI.01049-17. doi: 10.1128/JVI.01049.
    PubMed     Text format     Abstract available


  51. KAMAL RP, Blanchfield K, Belser JA, Music N, et al
    Inactivated H7 influenza virus vaccines protect mice despite low levels of neutralizing antibodies.
    J Virol. 2017 Aug 2. pii: JVI.01202-17. doi: 10.1128/JVI.01202.
    PubMed     Text format     Abstract available


  52. BRITT WJ
    Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    July 2017
  53. SENKEVICH TG, Katsafanas G, Weisberg A, Olano LR, et al
    Identification of Vaccinia Virus Replisome and Transcriptome Proteins by iPOND Coupled with Mass Spectrometry.
    J Virol. 2017 Jul 26. pii: JVI.01015-17. doi: 10.1128/JVI.01015.
    PubMed     Text format     Abstract available


  54. PHAN SI, Adam CM, Chen Z, Citron M, et al
    The genetic stability of PIV5-vectored RSV vaccine candidates after in vitro and in vivo passage.
    J Virol. 2017 Jul 26. pii: JVI.00559-17. doi: 10.1128/JVI.00559.
    PubMed     Text format     Abstract available


  55. PHAN SI, Zengel JR, Wei H, Li Z, et al
    Parainfluenza virus 5 (PIV5) expressing wild-type or pre-fusion respiratory syncytial virus (RSV) fusion protein protect mice and cotton rats from RSV challenge.
    J Virol. 2017 Jul 26. pii: JVI.00560-17. doi: 10.1128/JVI.00560.
    PubMed     Text format     Abstract available


  56. KUMAR J, Yadav VN, Phulera S, Kamble A, et al
    Species specificity of vaccinia virus complement control protein towards bovine classical pathway is governed primarily by direct interaction of its acidic residues with factor I.
    J Virol. 2017 Jul 19. pii: JVI.00668-17. doi: 10.1128/JVI.00668.
    PubMed     Text format     Abstract available


  57. WANG K, Tomaras GD, Jegaskanda S, Moody MA, et al
    Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate ADCC, and Protect Mice from Ocular Challenge with HSV-1
    J Virol. 2017 Jul 12. pii: JVI.00411-17. doi: 10.1128/JVI.00411.
    PubMed     Text format     Abstract available


  58. BOGERS WMJM, Barnett SW, Oostermeijer H, Nieuwenhuis IG, et al
    Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    J Virol. 2017 Jul 12. pii: JVI.00811-17. doi: 10.1128/JVI.00811.
    PubMed     Text format     Abstract available


  59. BAUER A, Podola L, Mann P, Missanga M, et al
    Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA prime - Modified Vaccinia Ankara (MVA) boost HIV-1 vaccine regimen.
    J Virol. 2017 Jul 12. pii: JVI.00730-17. doi: 10.1128/JVI.00730.
    PubMed     Text format     Abstract available


  60. DESROSIERS RC
    Protection against HIV Acquisition in the RV144 Trial.
    J Virol. 2017 Jul 12. pii: JVI.00905-17. doi: 10.1128/JVI.00905.
    PubMed     Text format     Abstract available


    June 2017
  61. KASANI SK, Cheng HY, Yeh KE, Chang SJ, et al
    Differential innate immune signaling in macrophages by wild type vaccinia mature virus and a mutant virus deleting A26 protein.
    J Virol. 2017 Jun 28. pii: JVI.00767-17. doi: 10.1128/JVI.00767.
    PubMed     Text format     Abstract available


  62. LENNEMANN NJ, Herbert AS, Brouillette R, Rhein B, et al
    Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.
    J Virol. 2017 Jun 14. pii: JVI.00479-17. doi: 10.1128/JVI.00479.
    PubMed     Text format     Abstract available


  63. BISCHOF GF, Magnani DM, Ricciardi M, Shin YC, et al
    Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector Against Dengue Virus in Rhesus Monkeys.
    J Virol. 2017 Jun 7. pii: JVI.00525-17. doi: 10.1128/JVI.00525.
    PubMed     Text format     Abstract available


  64. BALE S, Goebrecht G, Stano A, Wilson R, et al
    Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses.
    J Virol. 2017 Jun 7. pii: JVI.00443-17. doi: 10.1128/JVI.00443.
    PubMed     Text format     Abstract available


  65. MUNOZ-ALIA MA, Muller CP, Russell SJ
    Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  66. WANG D, Phan S, DiStefano DJ, Citron MP, et al
    A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    May 2017
  67. LEE SY, Lee YJ, Kim RH, Park JN, et al
    Rapid Engineering for Vaccine and Challenge Viruses against Foot-and-Mouth Disease.
    J Virol. 2017 May 31. pii: JVI.00155-17. doi: 10.1128/JVI.00155.
    PubMed     Text format     Abstract available


  68. LIANG B, Ngwuta JO, Surman S, Kabatova B, et al
    Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus (RSV) fusion protein in a vectored vaccine candidate.
    J Virol. 2017 May 24. pii: JVI.00189-17. doi: 10.1128/JVI.00189.
    PubMed     Text format     Abstract available


  69. RINGE RP, Ozorowski G, Rantalainen K, Struwe WB, et al
    Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers.
    J Virol. 2017 May 24. pii: JVI.00677-17. doi: 10.1128/JVI.00677.
    PubMed     Text format     Abstract available


  70. JIANG RT, Wang JW, Peng S, Huang TC, et al
    Spontaneous and vaccine-induced clearance of Mus musculus Papillomavirus type 1 (MmuPV1/MusPV1) infection.
    J Virol. 2017 May 17. pii: JVI.00699-17. doi: 10.1128/JVI.00699.
    PubMed     Text format     Abstract available


  71. OLSON AT, Rico AB, Wang Z, Delhon G, et al
    Deletion of the Vaccinia B1 Kinase Reveals Essential Functions of this Enzyme Complemented Partly by the Homologous Cellular Kinase VRK2.
    J Virol. 2017 May 17. pii: JVI.00635-17. doi: 10.1128/JVI.00635.
    PubMed     Text format     Abstract available


  72. SCOTT KA, Kotecha A, Seago J, Ren J, et al
    SAT2 Foot-and-Mouth Disease Virus Structurally Modified for Increased Thermostability.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  73. ZHANG L, Li H, Hai Y, Yin W, et al
    CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  74. BOONNAK K, Matsuoka Y, Wang W, Suguitan AL Jr, et al
    Development of clade-specific and broadly reactive live attenuated influenza virus vaccines against rapidly evolving H5 subtype viruses.
    J Virol. 2017 May 10. pii: JVI.00547-17. doi: 10.1128/JVI.00547.
    PubMed     Text format     Abstract available


  75. HYUN SI, Weisberg A, Moss B
    Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins.
    J Virol. 2017 May 10. pii: JVI.00558-17. doi: 10.1128/JVI.00558.
    PubMed     Text format     Abstract available


  76. CRUZ AGB, Han A, Roy EJ, Guzman AB, et al
    Deletion of the K1L gene results in a vaccinia virus that is less pathogenic due to muted innate immune responses, yet still elicits protective immunity.
    J Virol. 2017 May 10. pii: JVI.00542-17. doi: 10.1128/JVI.00542.
    PubMed     Text format     Abstract available


  77. SHEN X, Bogers WM, Yates NL, Ferrari G, et al
    Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    J Virol. 2017 May 10. pii: JVI.00401-17. doi: 10.1128/JVI.00401.
    PubMed     Text format     Abstract available


    April 2017
  78. FILSKOV J, Mikkelsen M, Hansen PR, Christensen JP, et al
    Broadening CD4+ and CD8+ T cell responses against hepatitis C virus by vaccination with NS3 overlapping peptide panels in cross-priming liposomes.
    J Virol. 2017 Apr 26. pii: JVI.00130-17. doi: 10.1128/JVI.00130.
    PubMed     Text format     Abstract available


  79. ZHANG Z, Dong Z, Li J, Carr MJ, et al
    Protective efficacy of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection.
    J Virol. 2017 Apr 19. pii: JVI.00333-17. doi: 10.1128/JVI.00333.
    PubMed     Text format     Abstract available


  80. DI PILATO M, Mejias-Perez E, Sorzano COS, Esteban M, et al
    Distinct roles of vaccinia virus NF-kB inhibitor proteins A52, B15 and K7 in the immune response.
    J Virol. 2017 Apr 19. pii: JVI.00575-17. doi: 10.1128/JVI.00575.
    PubMed     Text format     Abstract available


  81. LIU SA, Stanfield BA, Chouljenko VN, Naidu S, et al
    Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus Type-1(HSV-1) Vaccine Strain VC2 Expressing the Equine Herpesvirus-1 (EHV-1) Glycoprotein D (gD) Generates Anti-EHV-1 Immune Responses in Mice.
    J Virol. 2017 Apr 12. pii: JVI.02445-16. doi: 10.1128/JVI.02445.
    PubMed     Text format     Abstract available


  82. SANTOS JJ, Finch C, Sutton T, Obadan A, et al
    Development of an alternative modified live Influenza B virus vaccine.
    J Virol. 2017 Apr 5. pii: JVI.00056-17. doi: 10.1128/JVI.00056.
    PubMed     Text format     Abstract available


    March 2017
  83. ERMLER M, Kirkpatrick E, Sun W, Hai R, et al
    Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model.
    J Virol. 2017 Mar 29. pii: JVI.00286-17. doi: 10.1128/JVI.00286.
    PubMed     Text format     Abstract available


  84. SCHWENEKER M, Laimbacher AS, Zimmer G, Wagner S, et al
    Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles.
    J Virol. 2017 Mar 22. pii: JVI.00343-17. doi: 10.1128/JVI.00343.
    PubMed     Text format     Abstract available


  85. KWON HI, Kim YI, Park SJ, Song MS, et al
    Evaluation of the immune responses to and cross-protective efficacy of Eurasian H7 avian influenza viruses.
    J Virol. 2017 Mar 22. pii: JVI.02259-16. doi: 10.1128/JVI.02259.
    PubMed     Text format     Abstract available


  86. LUO H, Winkelmann E, Xie G, Fang R, et al
    MAVS Is Essential for Primary CD4+ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  87. BOYOGLU-BARNUM S, Todd SO, Meng J, Barnum TR, et al
    Mutating the CX3C motif in the G protein should make a live respiratory syncytial virus vaccine safer and more effective.
    J Virol. 2017 Mar 8. pii: JVI.02059-16. doi: 10.1128/JVI.02059.
    PubMed     Text format     Abstract available


  88. MENG X, Rose L, Han Y, Deng J, et al
    Vaccinia virus A6 is a two-domain protein requiring a cognate N-terminal domain for full viral membrane assembly activity.
    J Virol. 2017 Mar 8. pii: JVI.02405-16. doi: 10.1128/JVI.02405.
    PubMed     Text format     Abstract available


  89. CHUANG GY, Geng H, Pancera M, Xu K, et al
    Structure-Based Design of a Soluble Prefusion-Closed HIV-1-Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    J Virol. 2017 Mar 8. pii: JVI.02268-16. doi: 10.1128/JVI.02268.
    PubMed     Text format     Abstract available


  90. WIEGAND MA, Gori-Savellini G, Gandolfo C, Papa G, et al
    Respiratory syncytial virus (RSV) vaccine vectored by a stable chimeric and replication-deficient Sendai virus protects mice without inducing enhanced disease.
    J Virol. 2017 Mar 1. pii: JVI.02298-16. doi: 10.1128/JVI.02298.
    PubMed     Text format     Abstract available


  91. ZHANG Z, Dong Z, Wei Q, Carr MJ, et al
    A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.
    J Virol. 2017 Mar 1. pii: JVI.02450-16. doi: 10.1128/JVI.02450.
    PubMed     Text format     Abstract available


  92. LINGEMANN M, Liu X, Surman S, Liang B, et al
    Attenuated Human Parainfluenza Virus type 1 expressing Ebola Virus Glycoprotein GP Administered Intranasally is Immunogenic in African Green Monkeys.
    J Virol. 2017 Mar 1. pii: JVI.02469-16. doi: 10.1128/JVI.02469.
    PubMed     Text format     Abstract available


    February 2017
  93. GRANT CF, Carr BV, Kotecha A, van den Born E, et al
    The B cell response to foot-and-mouth disease virus in cattle following sequential vaccination with multiple serotypes.
    J Virol. 2017 Feb 22. pii: JVI.02157-16. doi: 10.1128/JVI.02157.
    PubMed     Text format     Abstract available


  94. HENSEL MT, Marshall JD, Dorwart MR, Heeke DS, et al
    Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reserv
    J Virol. 2017 Feb 22. pii: JVI.02257-16. doi: 10.1128/JVI.02257.
    PubMed     Text format     Abstract available


  95. MARTINEZ DR, Vandergrift N, Douglas AO, McGuire E, et al
    Maternal binding and neutralizing IgG responses targeting the C terminal region of the V3 loop are predictive of reduced peripartum HIV-1 transmission risk.
    J Virol. 2017 Feb 15. pii: JVI.02422-16. doi: 10.1128/JVI.02422.
    PubMed     Text format     Abstract available


  96. GO EP, Ding H, Zhang S, Ringe RP, et al
    A glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers.
    J Virol. 2017 Feb 15. pii: JVI.02428-16. doi: 10.1128/JVI.02428.
    PubMed     Text format     Abstract available


  97. ZURAWSKI G, Shen X, Zurawski S, Tomaras GD, et al
    Superiority in Rhesus Macaques of Targeting HIV-1 Env Gp140 to CD40 Versus LOX-1 in Combination with Replication Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    J Virol. 2017 Feb 15. pii: JVI.01596-16. doi: 10.1128/JVI.01596.
    PubMed     Text format     Abstract available


  98. BRAUN C, Thurmer A, Daniel R, Schultz AK, et al
    Genetic Variability of Myxoma Virus Genomes.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  99. GARCIA-ARRIAZA J, Perdiguero B, Heeney JL, Seaman MS, et al
    HIV/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived VLPs or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-specific B and T cell i
    J Virol. 2017 Feb 8. pii: JVI.02182-16. doi: 10.1128/JVI.02182.
    PubMed     Text format     Abstract available


  100. JIANG W, Wang S, Chen H, Ren H, et al
    A bivalent heterologous DNA-virus-like particles prime-boost vaccine elicits broad protection against both groups 1 and 2 influenza A viruses.
    J Virol. 2017 Feb 8. pii: JVI.02052-16. doi: 10.1128/JVI.02052.
    PubMed     Text format     Abstract available


  101. NASAR F, Matassov D, Seymour RL, Latham T, et al
    Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single dose protection against lethal alphavirus challenge.
    J Virol. 2017 Feb 1. pii: JVI.01729-16. doi: 10.1128/JVI.01729.
    PubMed     Text format     Abstract available


  102. HALEY SL, Tzvetkov EP, Meuwissen S, Plummer JR, et al
    Targeting Vaccine-induced Extrafollicular Pathway of B cell Differentiation Improves Rabies Post-exposure Prophylaxis.
    J Virol. 2017 Feb 1. pii: JVI.02435-16. doi: 10.1128/JVI.02435.
    PubMed     Text format     Abstract available


  103. SCHNEIDER-OHRUM K, Cayatte C, Snell Bennett A, Manohar Rajani G, et al
    Immunization with low doses of recombinant post-fusion or pre-fusion RSV F primes for vaccine-enhanced disease in the cotton rat model independent of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (Alum) adjuvant.
    J Virol. 2017 Feb 1. pii: JVI.02180-16. doi: 10.1128/JVI.02180.
    PubMed     Text format     Abstract available


  104. BUDASZEWSKI RD, Hudacek A, Sawatsky B, Kramer B, et al
    Inactivated Recombinant Rabies Viruses Displaying the Canine Distemper Virus Glycoproteins Induce Protective Immunity Against Both Pathogens.
    J Virol. 2017 Feb 1. pii: JVI.02077-16. doi: 10.1128/JVI.02077.
    PubMed     Text format     Abstract available


    January 2017
  105. ROYER DJ, Carr MM, Chucair-Elliott AJ, Halford WP, et al
    Impact of type 1 interferon on the safety and immunogenicity of an experimental live-attenuated herpes simplex virus type 1 vaccine in mice.
    J Virol. 2017 Jan 25. pii: JVI.02342-16. doi: 10.1128/JVI.02342.
    PubMed     Text format     Abstract available


  106. TANG X, Yang Y, Xia X, Zhang C, et al
    Recombinant adenoviruses displaying matrix 2 ectodomain epitopes (M2e) on their fiber proteins as universal influenza vaccines.
    J Virol. 2017 Jan 18. pii: JVI.02462-16. doi: 10.1128/JVI.02462.
    PubMed     Text format     Abstract available


  107. LI Y, Zhou M, Luo Z, Zhang Y, et al
    Overexpression of IL-7 extends the humoral immune response induced by rabies vaccination.
    J Virol. 2017 Jan 18. pii: JVI.02324-16. doi: 10.1128/JVI.02324.
    PubMed     Text format     Abstract available


  108. PREVOST J, Zoubchenok D, Richard J, Veillette M, et al
    Influence of the Envelope Gp120 Phe 43 Cavity on HIV-1 Sensitivity to ADCC Responses.
    J Virol. 2017 Jan 18. pii: JVI.02452-16. doi: 10.1128/JVI.02452.
    PubMed     Text format     Abstract available


  109. KIM SM, Kim YI, Park SJ, Kim EH, et al
    Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy.
    J Virol. 2017 Jan 11. pii: JVI.01693-16. doi: 10.1128/JVI.01693.
    PubMed     Text format     Abstract available


  110. VAN DEN HOECKE S, Ehrhardt K, Kolpe A, El Bakkouri K, et al
    Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies.
    J Virol. 2017 Jan 11. pii: JVI.02500-16. doi: 10.1128/JVI.02500.
    PubMed     Text format     Abstract available


  111. HA S, Li F, Troutman MC, Freed DC, et al
    Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targets Viral gH/gL/pUL128-131 Pentameric Complex.
    J Virol. 2017 Jan 11. pii: JVI.02033-16. doi: 10.1128/JVI.02033.
    PubMed     Text format     Abstract available


  112. VAN DEN POL AN, Mao G, Chattopadhyay A, Rose JK, et al
    Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
    J Virol. 2017 Jan 11. pii: JVI.02154-16. doi: 10.1128/JVI.02154.
    PubMed     Text format     Abstract available


  113. NAITO T, Mori K, Ushirogawa H, Takizawa N, et al
    Generation of a genetically stable high-fidelity influenza vaccine strain.
    J Virol. 2017 Jan 4. pii: JVI.01073-16. doi: 10.1128/JVI.01073.
    PubMed     Text format     Abstract available


  114. O'DONNELL V, Risatti GR, Holinka LG, Krug PW, et al
    Simultaneous Deletion of the 9GL and UK Genes from the African Swine Fever Virus Georgia 2007 Isolate Offers Increased Safety and Protection against Homologous Challenge.
    J Virol. 2016;91.
    PubMed     Text format     Abstract available


  115. TAI W, Wang Y, Fett CA, Zhao G, et al
    Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    J Virol. 2016;91.
    PubMed     Text format     Abstract available


  116. FIGUEIRA TN, Palermo LM, Veiga AS, Huey D, et al
    In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.
    J Virol. 2016;91.
    PubMed     Text format     Abstract available


    December 2016
  117. NIVARTHI UK, Kose N, Sapparapu G, Widman D, et al
    Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination.
    J Virol. 2016 Dec 28. pii: JVI.02041-16. doi: 10.1128/JVI.02041.
    PubMed     Text format     Abstract available


  118. DAI A, Cao S, Dhungel P, Luan Y, et al
    Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs During Vaccinia Virus-induced Host Shutoff.
    J Virol. 2016 Dec 21. pii: JVI.01858-16. doi: 10.1128/JVI.01858.
    PubMed     Text format     Abstract available


  119. LEE J, Hashimoto M, Im SJ, Araki K, et al
    Adenovirus serotype 5 vaccination results in suboptimal CD4 T helper 1 responses in mice.
    J Virol. 2016 Dec 21. pii: JVI.01132-16. doi: 10.1128/JVI.01132.
    PubMed     Text format     Abstract available


  120. EDUARDO-CORREIA B, Martinez-Romero C, Garcia-Sastre A, Guerra S, et al
    Correction for Eduardo-Correia et al., ISG15 Is Counteracted by Vaccinia Virus E3 Protein and Controls the Proinflammatory Response against Viral Infection.
    J Virol. 2016;90:11280.
    PubMed     Text format    


  121. ANGELO MA, Grifoni A, O'Rourke PH, Sidney J, et al
    Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity.
    J Virol. 2016 Dec 14. pii: JVI.02147.
    PubMed     Text format     Abstract available


  122. NOGALES A, Rodriguez L, Chauche C, Huang K, et al
    A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine.
    J Virol. 2016 Dec 7. pii: JVI.02211.
    PubMed     Text format     Abstract available


  123. CONE KR, Kronenberg ZN, Yandell M, Elde NC, et al
    Emergence of a viral RNA polymerase variant during gene copy number amplification promotes rapid evolution of vaccinia virus.
    J Virol. 2016 Dec 7. pii: JVI.01428.
    PubMed     Text format     Abstract available


  124. SHAW JM, Miller-Novak LK, Mohanram V, McKinnon K, et al
    Influence of Plasma Cell Niche Factors on the Recruitment and Maintenance of IRF4hi Plasma Cells and Plasmablasts in Vaccinated, SIV-Infected Rhesus Macaques with Low and High Viremia.
    J Virol. 2016 Dec 7. pii: JVI.01727.
    PubMed     Text format     Abstract available


  125. KASTURI SP, Kozlowski PA, Nakaya HI, Burger MC, et al
    Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5alpha restrictive macaques.
    J Virol. 2016 Dec 7. pii: JVI.01844.
    PubMed     Text format     Abstract available


    November 2016
  126. WANG Z, Li M, Zhou M, Zhang Y, et al
    A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells.
    J Virol. 2016 Nov 16. pii: JVI.01956.
    PubMed     Text format     Abstract available


  127. WIRBLICH C, Coleman CM, Kurup D, Abraham TS, et al
    One-Health: A Safe, Efficient Dual-use Vaccine for Humans and Animals against MERS-CoV and Rabies Virus.
    J Virol. 2016 Nov 2. pii: JVI.02040.
    PubMed     Text format     Abstract available


  128. CROSBY CM, Matchett WE, Anguiano-Zarate SS, Parks CA, et al
    Replicating Single-cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.
    J Virol. 2016 Nov 2. pii: JVI.00720.
    PubMed     Text format     Abstract available


    October 2016
  129. CELMA CC, Stewart M, Wernike K, Eschbaumer M, et al
    Replication-deficient particles: New insights into the next generation of bluetongue virus vaccines.
    J Virol. 2016 Oct 26. pii: JVI.01892.
    PubMed     Text format     Abstract available


  130. LOGAN M, Law J, Wong JA, Hockman D, et al
    Native folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG.
    J Virol. 2016 Oct 19. pii: JVI.01552.
    PubMed     Text format     Abstract available


  131. JIANG X, Totrov M, Li W, Sampson JM, et al
    Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    J Virol. 2016 Oct 5. pii: JVI.01409.
    PubMed     Text format     Abstract available


    September 2016
  132. ROUXEL RN, Tafalla C, Merour E, Leal E, et al
    Attenuated Infectious Hematopoietic Necrosis Virus (IHNV) with rearranged gene order as potential vaccine.
    J Virol. 2016 Sep 28. pii: JVI.01024.
    PubMed     Text format     Abstract available


  133. LI D, von Schaewen M, Wang X, Tao W, et al
    Altered glycosylation patterns increase immunogenicity of a subunit HCV vaccine inducing neutralizing antibodies which confer protection in mice.
    J Virol. 2016 Sep 14. pii: JVI.01462.
    PubMed     Text format     Abstract available


  134. ZOLLA-PAZNER S, Powell R, Yahyaei S, Williams C, et al
    RATIONALLY-DESIGNED VACCINES TARGETING THE V2 REGION OF HIV-1 gp120 INDUCE A FOCUSED, CROSS CLADE-REACTIVE, BIOLOGICALLY FUNCTIONAL ANTIBODY RESPONSE.
    J Virol. 2016 Sep 14. pii: JVI.01403.
    PubMed     Text format     Abstract available


  135. COSTA M, Pollara J, Edwards RW, Seaman M, et al
    Fc receptor mediated activities by Env-specific human mAbs generated from volunteers receiving the DNA prime-protein boost HIV vaccine DP6-001.
    J Virol. 2016 Sep 14. pii: JVI.01458.
    PubMed     Text format     Abstract available


    August 2016
  136. HARRISON K, Haga IR, Pechenick Jowers T, Jasim S, et al
    Vaccinia virus uses retromer-independent cellular retrograde transport pathways to facilitate the wrapping of intracellular mature virions during viral morphogenesis.
    J Virol. 2016 Aug 31. pii: JVI.01464.
    PubMed     Text format     Abstract available


  137. SCHNEIDER-OHRUM K, Cayatte C, Liu Y, Wang Z, et al
    Production of cytomegalovirus dense bodies by scalable bioprocess methods maintains immunogenicity and improves neutralizing antibody titers.
    J Virol. 2016 Aug 31. pii: JVI.00463.
    PubMed     Text format     Abstract available


  138. WIBMER CK, Gorman J, Anthony CS, Mkhize NN, et al
    Structure of an N276-dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole adjacent to the CD4 Binding Site.
    J Virol. 2016 Aug 31. pii: JVI.01357.
    PubMed     Text format     Abstract available


  139. ALTENBURG AF, van de Sandt CE, van Trierum SE, De Gruyter HL, et al
    Increased Protein Degradation Improves Influenza Virus Nucleoprotein-specific CD8+ T cell Activation in vitro but not in C57BL/6 mice.
    J Virol. 2016 Aug 31. pii: JVI.01633.
    PubMed     Text format     Abstract available


  140. LIANG B, Ngwuta JO, Herbert R, Swerczek J, et al
    Packaging and prefusion stabilization separately and additively increase the quantity and quality of RSV-neutralizing antibodies induced by respiratory syncytial virus (RSV) fusion protein expressed by a parainfluenza vector.
    J Virol. 2016 Aug 31. pii: JVI.01196.
    PubMed     Text format     Abstract available


  141. NGO T, Mirzakhanyan Y, Moussatche N, Gershon PD, et al
    Protein primary structure of the Vaccinia virion at increased resolution.
    J Virol. 2016 Aug 24. pii: JVI.01042.
    PubMed     Text format     Abstract available


  142. LIU L, Zeng X, Chen P, Deng G, et al
    Characterization of Clade 7.2 H5 Avian Influenza Viruses That Continue to Circulate in Chickens in China.
    J Virol. 2016 Aug 24. pii: JVI.00855.
    PubMed     Text format     Abstract available


  143. AYALA VI, Trivett MT, Barsov EV, Jain S, et al
    Adoptive Transfer of Engineered Rhesus SIV-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques.
    J Virol. 2016 Aug 24. pii: JVI.01522.
    PubMed     Text format     Abstract available


  144. VERKERKE HP, Williams JA, Guttman M, Simonich CA, et al
    Epitope-independent purification of native-like envelope trimers from diverse HIV-1 isolates.
    J Virol. 2016 Aug 10. pii: JVI.01351.
    PubMed     Text format     Abstract available


  145. TALKER SC, Stadler M, Koinig HC, Mair KH, et al
    Influenza A virus infection in pigs attracts multifunctional and cross-reactive T cells to the lung.
    J Virol. 2016 Aug 10. pii: JVI.01211.
    PubMed     Text format     Abstract available


  146. LIANG Y, Guttman M, Williams JA, Verkerke H, et al
    Changes in structure and antigenicity of HIV-1 Env trimers resulting from removal of a conserved CD4 binding site-proximal glycan.
    J Virol. 2016 Aug 3. pii: JVI.01116.
    PubMed     Text format     Abstract available


    July 2016
  147. IYER SS, Gangadhara S, Victor B, Shen X, et al
    Virus-like particles displaying trimeric SIV envelope gp160 enhance the breadth of DNA/MVA SIV vaccine induced antibody responses in rhesus macaques.
    J Virol. 2016 Jul 27. pii: JVI.01163.
    PubMed     Text format     Abstract available


  148. SIVAN G, Weisberg AS, Americo JL, Moss B, et al
    Retrograde Transport from Early Endosomes to the Trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virions.
    J Virol. 2016 Jul 27. pii: JVI.01114.
    PubMed     Text format     Abstract available


  149. LIU WC, Jan JT, Huang YJ, Chen TH, et al
    Unmasking stem-specific neutralizing epitopes by abolishing N-linked glycosylation sites of influenza hemagglutinin proteins for vaccine design.
    J Virol. 2016 Jul 20. pii: JVI.00880.
    PubMed     Text format     Abstract available


  150. ZHOU B, Meliopoulos VA, Wang W, Lin X, et al
    Reversion of Cold-adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.
    J Virol. 2016 Jul 20. pii: JVI.00163.
    PubMed     Text format     Abstract available


  151. GACH JS, Venzon D, Vaccari M, Keele BF, et al
    The relationship between vaccine-induced antibody capture of infectious virus and infection outcomes following low-dose, repeated rectal challenge with SIVmac251.
    J Virol. 2016 Jul 20. pii: JVI.00812.
    PubMed     Text format     Abstract available


  152. DEPLEDGE DP, Yamanishi K, Gomi Y, Gershon A, et al
    Deep-sequencing of distinct preparations of the live-attenuated VZV vaccine reveals a conserved core of attenuating SNPs.
    J Virol. 2016 Jul 20. pii: JVI.00998.
    PubMed     Text format     Abstract available


  153. TOWNSLEY S, Mohamed Z, Guo W, McKenna J, et al
    Induction of heterologous Tier 2 HIV-1 neutralizing and cross-reactive V1/V2-specific antibodies in rabbits by prime-boost immunization.
    J Virol. 2016 Jul 20. pii: JVI.00853.
    PubMed     Text format     Abstract available


    June 2016
  154. CHOI KY, Root M, McGregor A
    A Novel Non-Replication Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.
    J Virol. 2016 Jun 22. pii: JVI.00283.
    PubMed     Text format     Abstract available


  155. LIU R, Moss B
    Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR/Cas9 Knock-Out Cell Lines and Vaccinia Virus Mutants.
    J Virol. 2016 Jun 22. pii: JVI.00869.
    PubMed     Text format     Abstract available


  156. ROSTAD CA, Stobart CC, Gilbert BE, Pickles RJ, et al
    A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats.
    J Virol. 2016 Jun 8. pii: JVI.00012.
    PubMed     Text format     Abstract available


  157. LULLA V, Lulla A, Wernike K, Aebischer A, et al
    Assembly of replication-incompetent African horse sickness virus particles: rational design of vaccines for all serotypes.
    J Virol. 2016 Jun 8. pii: JVI.00548.
    PubMed     Text format     Abstract available


  158. JENSEN K, Nabi R, Van Rompay KK, Robichaux S, et al
    Vaccine-elicited mucosal and systemic antibody responses are associated with reduced simian immunodeficiency viremia in infant rhesus macaques.
    J Virol. 2016 Jun 1. pii: JVI.00481.
    PubMed     Text format     Abstract available


  159. CASTRO I, Giret TM, Magnani DM, Maxwell HS, et al
    Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons.
    J Virol. 2016;90:5280-91.
    PubMed     Text format     Abstract available


    May 2016
  160. KO EJ, Lee YT, Kim KH, Jung YJ, et al
    MF59 adjuvant effects on inducing isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells.
    J Virol. 2016 May 25. pii: JVI.00339.
    PubMed     Text format     Abstract available


  161. LEE YT, Ko EJ, Lee Y, Lee YN, et al
    CD47 plays a role as a negative regulator in inducing protective immune responses to vaccination against influenza virus.
    J Virol. 2016 May 18. pii: JVI.00605.
    PubMed     Text format     Abstract available


  162. KAMLANGDEE A, Kingstad-Bakke B, Osorio JE
    Mosaic H5 hemagglutinin provides broad humoral and cellular immune responses against influenza viruses.
    J Virol. 2016 May 18. pii: JVI.00730.
    PubMed     Text format     Abstract available


  163. LARSEN IV, Clausius H, Kolb AW, Brandt CR, et al
    Both CD8+ and CD4+ T-Cells Contribute to Corneal Clouding and Viral Clearance Following Vaccinia Virus Infection in C57BL/6 Mice.
    J Virol. 2016 May 11. pii: JVI.00570.
    PubMed     Text format     Abstract available


    April 2016
  164. TAYLOR A, Melton JV, Herrero LJ, Thaa B, et al
    Effects of an In-Frame Deletion of the 6k Gene Locus from the Genome of Ross River Virus.
    J Virol. 2016;90:4150-9.
    PubMed     Text format     Abstract available


    March 2016
  165. LAZEAR HM, Diamond MS
    Zika Virus: New Clinical Syndromes and its Emergence in the Western Hemisphere.
    J Virol. 2016 Mar 9. pii: JVI.00252.
    PubMed     Text format     Abstract available


  166. NELSON CS, Pollara J, Kunz EL, Jeffries TL Jr, et al
    Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces Robust IgA-Isotype B Cell Response in Breast Milk.
    J Virol. 2016 Mar 2. pii: JVI.00335.
    PubMed     Text format     Abstract available


  167. IWASAKI M, Cubitt B, Sullivan BM, de la Torre JC, et al
    The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
    J Virol. 2016;90:3187-97.
    PubMed     Text format     Abstract available


    February 2016
  168. DIAZ-SAN SEGUNDO F, Medina GN, Ramirez-Medina E, Velazquez-Salinas L, et al
    Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response.
    J Virol. 2015;90:1298-310.
    PubMed     Text format     Abstract available


  169. YEN LC, Liao JT, Lee HJ, Chou WY, et al
    The C Terminus of the Core beta-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.
    J Virol. 2015;90:1178-89.
    PubMed     Text format     Abstract available


    January 2016
  170. SEN N, Arvin AM
    Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.
    J Virol. 2016;90:3284-7.
    PubMed     Text format     Abstract available


  171. CHEN CJ, Ermler ME, Tan GS, Krammer F, et al
    Influenza A viruses expressing intra- or inter-group chimeric hemagglutinins.
    J Virol. 2016 Jan 13. pii: JVI.03060.
    PubMed     Text format     Abstract available


  172. PATIL S, Kumar R, Deshpande S, Samal S, et al
    Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in V1 Loop.
    J Virol. 2016 Jan 13. pii: JVI.03090.
    PubMed     Text format     Abstract available


  173. DINIS JM, Florek NW, Fatola OO, Moncla LH, et al
    Deep sequencing reveals potential antigenic variants at low frequency in influenza A-infected humans.
    J Virol. 2016 Jan 6. pii: JVI.03248.
    PubMed     Text format     Abstract available


    December 2015
  174. CHENG C, Pancera M, Bossert A, Schmidt SD, et al
    Immunogenicity of a Prefusion HIV-1-Envelope Trimer in Complex with a Quaternary-Specific Antibody.
    J Virol. 2015 Dec 30. pii: JVI.02380.
    PubMed     Text format     Abstract available


  175. NACHBAGAUER R, Miller MS, Hai R, Ryder AB, et al
    Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets.
    J Virol. 2015 Dec 30. pii: JVI.02481.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: